Epipen and Epipen Junior (adrenaline auto-injector devices) will be subject to limited availability for the remainder of 2018. Mylan are currently (September 2018) out-of-stock of EpiPen Junior, with continued interruptions in supply anticipated in the coming months.
Information about the supply situation, as well as recommended courses of action to help manage the consequences will be posted on this page and maintained as new information becomes available.
Below you can find:
- a copy of the supply disruption alert from the Department of Health and Social Care
- a copy of British Society for Allergy and Clinical Immunology (BSACI) guidance on prescribing an adrenaline auto-injector
- a document from SPS summarising key differences between the 3 available presentations of adrenaline prefilled syringes/auto-injectors
- two documents from NHS Improvement advising on methods to preserve existing stock in primary care
- a document from the Department of Health and Social Care giving advice to schools
- a letter from Dr Aidan Fowler, National Director of Patient Safety, giving advice to parents and guardians of children on the issue
- a letter to Healthcare Professionals from ALK concerning extended use for selected lots of Jext adrenaline auto-injectors
- a dispensing protocol for 150 microgram adrenaline auto-injectors
- a Q&A document for pharmacies and dispensing practices concerning adrenaline auto-injectors
Assistant Head (Medicines Optimisation), Specialist Pharmacy Service